Sunshine Heart raises $5M, readies for C-Pulse trials

Sunshine Heart, a cardiac device company based in Eden Prairie, MN and Australia, has raised A$4.6 million ($5.03 million) by selling 115 million shares with institutional investors. The company is developing an implantable device to treat moderate to severe heart failure. The device, called the C-Pulse Heart Assist System, has been granted approval to conduct a feasibility clinical trial.

The device takes care of heart-failure symptoms by using a balloon counter-pulsation technology that takes a load off the left ventricle of the heart. The balloon inflates and deflates in sync with the patient's heartbeat, much like a pacemaker.

Sunshine wants to raise another A$9.1 million ($10 million) in August. In December 2010, the company completed A$9.5 million in financing via a rights issue to existing shareholders. In September, the company raised A$3.7 million via similar means.

"The continued confidence demonstrated by the investment community exemplifies the growing excitement around the C-Pulse Heart Assist System for treatment of Class III and ambulatory Class IV heart failure," said Dave Rosa, Sunshine Heart's chief executive officer, in a release.

- read the story in MedCity News

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.